Cargando…

A Rare Case of Ixazomib-Induced Cutaneous Necrotizing Vasculitis in a Patient with Relapsed Myeloma

Ixazomib is the only oral proteasome inhibitor used in relapsed/refractory myeloma. Cutaneous side effects due to ixazomib have been documented in the literature; however, cutaneous necrotizing vasculitis is extremely rare. We describe a case of a 74-year-old man with relapsed multiple myeloma who w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Katz, Heather, Shenouda, Mina, Dahshan, Deena, Sonnier, George, Lebowicz, Yehuda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6855061/ https://www.ncbi.nlm.nih.gov/pubmed/31781426 http://dx.doi.org/10.1155/2019/6061484

Ejemplares similares

Ixazomib–Thalidomide–Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma
por: Ludwig, Heinz, et al.
Publicado: (2019)

New developments in the management of relapsed/refractory multiple myeloma – the role of ixazomib
por: Richardson, Paul G, et al.
Publicado: (2017)

Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
por: Kumar, S K, et al.
Publicado: (2015)

Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma
por: Dhakal, Binod, et al.
Publicado: (2019)

Subdural Hygroma: A Morbid Complication of Intrathecal Chemotherapy in a Patient with B-Cell Acute Lymphocytic Leukemia
por: Shenouda, Mina, et al.
Publicado: (2019)

Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma
por: Krishnan, Amrita, et al.
Publicado: (2018)

Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma
por: Kumar, Shaji, et al.
Publicado: (2017)

Extraosseous Ewing Sarcoma Presenting with Inferior ST-Elevation Myocardial Infarction and Systemic Emboli due to Tumor Thrombus and Invasion of the Left Atrium
por: Dotson, Jennifer, et al.
Publicado: (2020)

Spotlight on ixazomib: potential in the treatment of multiple myeloma
por: Muz, Barbara, et al.
Publicado: (2016)

T‐cell pseudolymphoma secondary to ixazomib for multiple myeloma
por: Haq, M., et al.
Publicado: (2021)

Real World Efficacy and Safety Results of Ixazomib Lenalidomide and Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program
por: Varga, Gergely, et al.
Publicado: (2019)

Efficacy of ixazomib for the treatment of relapsed/refractory multiple myeloma: A protocol of systematic review and meta-analysis
por: Li, Zhi, et al.
Publicado: (2020)

Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results
por: Auner, Holger W., et al.
Publicado: (2022)

PB2164: EFFICACY AND SAFETY EVALUATION OF IXAZOMIB, POMALIDOMIDE, AND DEXAMETHASONE IN THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: LI, Wen, et al.
Publicado: (2023)

Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study
por: Macro, M., et al.
Publicado: (2023)

Ixazomib: An Oral Proteasome Inhibitor for the Treatment of Multiple Myeloma
por: Ramirez, Krista G.
Publicado: (2017)

Accidental Ixazomib Overdose in a Patient With Multiple Myeloma
por: Sampat, Parth J., et al.
Publicado: (2021)

Cutaneous necrotizing small‐vessel vasculitis induced by acute hepatitis E
por: Viallard, Jean‐François, et al.
Publicado: (2019)

Safety Profile of Ixazomib in Patients with Relapsed/Refractory Multiple Myeloma in Japan: An All-case Post-marketing Surveillance
por: Kakimoto, Yoshihide, et al.
Publicado: (2021)

Cutaneous presentation of Double Hit Lymphoma: A Case Report With Review of the Literature
por: Khelfa, Yousef, et al.
Publicado: (2016)

Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance
por: Kumar, Shaji K., et al.
Publicado: (2019)

Pharmacokinetics and safety of ixazomib plus lenalidomide–dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study
por: Gupta, Neeraj, et al.
Publicado: (2015)

Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses
por: Gupta, Neeraj, et al.
Publicado: (2017)

P11: IXAZOMIB WITH CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MYELOMA: MUKEIGHT PHASE II RANDOMISED CONTROLLED TRIAL RESULTS
por: Auner, H, et al.
Publicado: (2022)

Efficacy and Safety of Ixazomib Plus Lenalidomide and Dexamethasone Following Injectable PI-Based Therapy in Relapsed/Refractory Multiple Myeloma
por: Abe, Yu, et al.
Publicado: (2023)

De novo and relapsing necrotizing vasculitis after COVID-19 vaccination
por: Fillon, Alexandre, et al.
Publicado: (2021)

Cutaneous Necrotizing Vasculitis and Leukopenia in a Cocaine User: Is Levamisole the Culprit?
por: El Khoury, Lara, et al.
Publicado: (2016)

Comparison of health technology assessment for new medicines in France and England: an example based on ixazomib for patients with relapsed or refractory multiple myeloma
por: Armoiry, Xavier, et al.
Publicado: (2019)

Correction to: Efficacy and safety of ixazomib plus lenalidomide and dexamethasone following injectable pi‑based therapy in relapsed/refractory multiple myeloma
por: Abe, Yu, et al.
Publicado: (2023)

Comparison between ixazomib+cyclophosphamide+dexamethasone regimen and ixazomib+dexamethasone regimen for elderly and frail patients having newly diagnosed multiple myeloma
por: Li, Shutan, et al.
Publicado: (2022)

Cutaneous involvement in relapsed multiple myeloma
por: Salle, Valéry, et al.
Publicado: (2022)

Stem Cell Mobilization with Ixazomib and G-CSF in Patients with Multiple Myeloma
por: Bühler, Selina, et al.
Publicado: (2023)

Relapsing Cutaneous Multiple Myeloma Responding to Immunochemotherapy: A Rare Case Report
por: Mohamed, Mujtaba, et al.
Publicado: (2019)

Recurrent cutaneous necrotizing eosinophilic vasculitis: a case report and review of the literature
por: Li, Wenfei, et al.
Publicado: (2013)

Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy
por: Minarik, Jiri, et al.
Publicado: (2022)

P929: CIRCULATING TUMOR DNA ASSESSMENT IMPROVES PROGNOSTIC PREDICTION IN RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING IXAZOMIB, LENALIDOMIDE, AND DEXAMETHASONE
por: Kogure, Yasunori, et al.
Publicado: (2023)

Cutaneous polyarteritis nodosa: A rare isolated cutaneous vasculitis
por: Subbanna, Praveen Kumar A., et al.
Publicado: (2012)

Ixazomib-associated tumor lysis syndrome in multiple myeloma: A case report
por: Jin, Fengbo, et al.
Publicado: (2020)

Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma
por: Patel, Krina K., et al.
Publicado: (2022)

PEG@ Carbon Nanotubes Composite as an Effective Nanocarrier of Ixazomib for Myeloma Cancer Therapy
por: Elgamal, Hanady A., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v4jt4q1uepi9i4vkni6oqi870j